UBS Group’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
– Sell
-173
Closed -$10K – 8736
2020
Q2
$10K Sell
173
-3,089
-95% -$191K ﹤0.01% 7053
2020
Q1
$194K Sell
3,262
-10,537
-76% -$614K ﹤0.01% 4747
2019
Q4
$756K Buy
13,799
+2,369
+21% +$88.5K ﹤0.01% 4474
2019
Q3
$323K Buy
11,430
+9,788
+596% +$359K ﹤0.01% 4892
2019
Q2
$55K Buy
+1,642
New +$51.3K ﹤0.01% 5845
2019
Q1
– Sell
-2,113
Closed -$58K – 8429
2018
Q4
$58K Buy
+2,113
New +$54.4K ﹤0.01% 5972

Other funds holding PRNB

UBS Group's PRNB Position: Q3 2020 in Review

UBS Group sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 173 shares — an estimated $10K sold.

UBS Group first reported a position in PRNB in Q4 2018 and held it in 6 quarters. The position peaked at $756K in Q4 2019. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • UBS Group reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • UBS Group sold 173 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $10K.
  • UBS Group first reported a position in Principia Biopharma Inc. Common Stock in Q4 2018 and held it in 6 quarters.
  • UBS Group's Principia Biopharma Inc. Common Stock position peaked at $756K in Q4 2019.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.